ArticleClinical and experimental medicine2025
Prognostic impact of somatic mutations and additional chromosomal abnormalities in patients with myelodysplastic syndromes and chromosome 20q deletion.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The 20q deletion (del(20q)) is a recurrent chromosomal abnormality in individuals with myelodysplastic syndrome (MDS) and is associated with favourable outcomes when isolated. This study aims to analyse the clinical features and prognostic impact of del(20q) based on cytogenetic and molecular alterations. Among 1,527 patients with MDS, 101 (6.6%) exhibited del(20q): 67 (66.3%) had isolated del(20q), 16 (15.8%) had one additional chromosome abnormality (ACA), and 18 (17.8%) had ≥ 2 additional chromosome abnormalities (ACAs). Patients with ≥ 2 ACAs experienced shorter overall survival (OS) (12 months vs. 35 months vs. 24 months, respectively, p = 0.046) and leukaemia-free survival (LFS) (NR vs. NR vs. 22 months, respectively, p = 0.030), than those with one ACA or isolated del(20q). The del(20q) with ACAs subgroup had a higher incidence of ≥ 2 mutations and a greater median number of molecular mutations (p = 0.049 and p = 0.047, respectively). Interestingly, we found that multiple mutations within the same gene were present in 8.7% (6/69) of the analyzed samples. Notably, TET2 was the most frequently observed gene with multiple mutations, constituting 66.7% (4/6) of all cases. Furthermore, samples with TET2 mutations exhibited a significantly higher median number of mutations compared to those without TET2 mutations (3.0 [Interquartile Range [IQR], 1, 4] vs. 1.0[0, 2], p = 0.003). Patients with ≥ 2 mutations showed poorer OS and LFS (p < 0.001 and p = 0.007, respectively) compared to those with fewer mutations. The presence of multiple mutations (hazard ratio [HR] = 2.777, p = 0.049), U2AF1 mutations (HR = 3.595, p = 0.010), TET2 mutations (HR = 7.178, p = 0.002), and bone marrow blasts ≥ 10% (HR = 5.727, p = 0.002) were independently associated with poorer OS. In summary, del(20q) with ACAs is associated with more molecular abnormalities, increased risk of acute myeloid leukaemia transformation, and shorter OS than isolated del(20q). U2AF1 and TET2 mutations predict poor prognosis in patients with del(20q) MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.